Project Grant R01CA298244
- Federal Grant Award Summary Rutgers The State University of New Jersey received a $516,808 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026 through May 31, 2031. The award supports research to elucidate the mechanism of targeting methionine synthase (MTR) to enhance anti-tumor immunity in KRAS-driven lung cancer. The research focuses on understanding how MTR, a key enzyme in one-carbon metabolism,...
- Federal Project Grant Award Summary Rutgers The State University of New Jersey, Robert Wood Johnson School of Health Sciences (RBHS-School of Nursing) received a $170,930 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective April 1, 2026 through March 31, 2028. The project, titled "Longitudinal Dynamics of Blood Microbiome and Circulating Tumor Cell in Metastatic Breast Cancer," delivers fundamental research...
- Federal Project Grant Award Summary Rutgers The State University of New Jersey (RBHS-School of Nursing) received a $197,414 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) on August 7, 2025, with completion targeted for July 31, 2030. This award supports a K01 (Mentored Research Development) grant designed to develop an early-career investigator's research capacity and expertise in studying dyadic and social network influences...
- Federal Grant Award Summary Rutgers The State University of New Jersey, Robert Wood Johnson Health Sciences (RBHS)-School of Nursing received a $403,689 Project Grant award from the National Cancer Institute (NCI) effective August 1, 2025, through July 31, 2027, under the Cancer Cause and Prevention Research program (CFDA 93.393). The grant funds research investigating the influence of menthol cigarette smoking on lung cancer screening eligibility within a national prospective cohort study....
- Federal Grant Award Summary Hackensack University Medical Center received a $467,261 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded May 1, 2026, with completion targeted for April 30, 2028. The research project, titled "Myeloid Phagocyte Activation by Commensal-Activated Complement C5AR1 Signaling: Implications for Tumor-Directed Lymphocyte Response," investigates the mechanisms by which...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Rutgers The State University of New Jersey, Robert Wood Johnson Medical School (RBHS-School of Nursing), a $654,688 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective April 1, 2026, through March 31, 2031. This five-year research initiative will conduct a comprehensive retrospective analysis of flavored cigar policy implementation across U.S. municipalities to identify effective...
- Federal Grant Award Summary The National Cancer Institute awarded a $122,610 Project Grant to the University of Pennsylvania on August 11, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award, with a completion date of July 31, 2030, supports the development of a system to advance National Cancer Institute (NCI)-sponsored clinical trials for patients with rare gastrointestinal malignancies and rare disease populations. The project leverages the principal investigator's...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant totaling $682,673 under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026, with completion targeted for April 30, 2031. This award funds research investigating the adaptation and evolution of resistance to pan-RAS inhibition in pancreatic ductal adenocarcinoma (PDAC), a disease responsible for over 52,000 annual deaths in...
- Federal Grant Award Summary Rutgers The State University of New Jersey received a $249,000 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 1, 2025, through July 31, 2028. The award supports fundamental research investigating protein condensates and nuclear organization mechanisms in genomic integrity. Specifically, the research characterizes how tumor suppressors BRCA1...
- Federal Grant Award Summary The University of Cincinnati received a $162,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2027. This award funds research to develop and evaluate novel combination treatment strategies targeting colorectal cancer patients with KRAS mutations. The project specifically investigates the efficacy of combining KRAS inhibitors with HER3 (human epidermal...
Rutgers The State University of New Jersey (RBHS-School of Nursing) received a $542,316 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective May 7, 2026, with completion targeted for April 30, 2031. The award funds research investigating the mechanism and therapeutic potential of parkin, an E3 ubiquitin ligase, in colorectal cancer (CRC) suppression. The research addresses the clinical significance of parkin downregulation in CRC patients and aims to develop novel molecular targets and therapeutic strategies by examining how parkin regulates metabolism through ubiquitination and degradation of key metabolic enzymes. The research deliverables focus on delineating parkin's tumor-suppressive mechanisms in CRC and identifying therapeutic approaches for parkin-deficient cancers. Through unbiased screening methodologies including LC-MS/MS-based protein-protein interaction analysis and quantitative proteomic analysis, the funded research will characterize metabolic reprogramming pathways in CRC and evaluate small molecule inhibitors targeting identified metabolic enzymes. The outcomes will advance understanding of metabolic alterations in cancer progression and provide evidence-based therapeutic strategies applicable to CRC treatment development.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $542.3k | 5/7/26 |